Eryonucu, BTuncer, MErkoc, R2025-05-102025-05-1020040920-32061573-724110.1007/s10557-004-6228-92-s2.0-16844371368https://doi.org/10.1007/s10557-004-6228-9https://hdl.handle.net/20.500.14720/14719Reha, Erkoc/0009-0001-7230-8843The GPIIb/IIIa inhibitors are used in the acute coronary syndromes and interventional cardiology as antiplatelet agents. These drugs induce thrombocytopenia in approximately 1 - 5% of patients. Thrombocytopenia is rapid in onset and antibody mediated. Abciximab is associated with higher incidence of thrombocytopenia than eptifibatide and tirofiban. Profound thrombocytopenia has reportedly been an issue with abciximab, but not with tirofiban. We reported a case of acute profound thrombocytopenia due to on tirofiban treatment in the same patient at two different times.eninfo:eu-repo/semantics/closedAccessThrombocytopeniaTirofibanArticle186Q2Q150350515770438WOS:000227699800011